After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. The stock was recently discussed on Yahoo Finance as it revealed that Inari Medical Reports Fourth Quarter 2023 Financial Results.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
NARI belongs to the Healthcare sector of the NASDAQ while operating in the Medical Devices industry. At the end of the last regular session, the stock closed at $58.26 and fluctuated between $59.13 as its day high and $57.28 as its day low. The current market capitalization of Inari Medical Inc is $3.36B. A total of 0.94 million shares were traded on the day, compared to an average of 634.94K shares.
Insider Activity
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, NARI has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 29 BUYs and 152 SELLs from insiders. Insiders purchased 1,980,098 shares during that period but sold 605,750.
In the most recent transaction, Hoffman William sold 25,000 shares of NARI for 65.08 per share on Dec 15. After the transaction, the Director now owns 1,045,493 company shares. In a previous transaction on Dec 12, Hill, Mitch C. sold 6,500 shares at 62.75 per share. NARI shares that Chief Financial Officer owns now total 170,230.
Among the insiders who sold shares, Hykes Andrew disposed of 37,448 shares on Nov 16 at a per-share price of $59.82. This resulted in the President and CEO holding 434,817 shares of NARI after the transaction. In another insider transaction, Tu Thomas sold 25,451 shares at $59.82 per share on Nov 16. Company shares held by the Chief Medical Officer now total 320,932.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for NARI in the last 3 months, the mean price target is $80.82 with high estimates of $100.00 and low estimates of $63.00. In terms of 52-week highs and lows, NARI has a high of $71.85 and a low of $47.81.
As of this writing, NARI has an earnings estimate of $0.01 per share for the current quarter. EPS was calculated based on a consensus of 10 estimates, with a high estimate of $0.08 per share and a lower estimate of -$0.06. The company reported an EPS of $0.04 in the last quarter, which was 130.80% higher than expectations of -$0.13.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. NARI’s latest balance sheet shows that the firm has $176.10M in Cash & Short Term Investments as of fiscal 2021. There were $29.21M in debt and $42.51M in liabilities at the time. Its Book Value Per Share was $7.86, while its Total Shareholder’s Equity was $239.21M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NARI is Buy with a score of 4.67.
